BioModelsapplication/xmlhttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002.pdfhttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002-biopax2.owlhttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002-biopax3.owlhttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002_urn.xmlhttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002_url.xmlhttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002.xpphttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002.scihttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002.pnghttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002.vcmlhttps://www.ebi.ac.uk/biomodels/model/download/MODEL1012220002?filename=MODEL1012220002.mprimary200OKVijayalakshmi ChelliahNon-curatedL2V1https://www.ebi.ac.uk/biomodels/MODEL101222000221179025falseBioModelsSBMLModelsCaron2010 mTOR SignalingNetwork2010MODEL1012220002Non KineticEtienne Caron, Samik Ghosh, Yukiko Matsuoka, Dariel Ashton-Beaucage, Marc Therrien, Sébastien Lemieux, Claude Perreault, Philippe P Roux, Hiroaki KitanoEtienne Caron21179025, The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and proliferation. mTOR signaling is frequently dysregulated in oncogenic cells, and thus an attractive target for anticancer therapy. Using CellDesigner, a modeling support software for graphical notation, we present herein a comprehensive map of the mTOR signaling network, which includes 964 species connected by 777 reactions. The map complies with both the systems biology markup language (SBML) and graphical notation (SBGN) for computational analysis and graphical representation, respectively. As captured in the mTOR map, we review and discuss our current understanding of the mTOR signaling network and highlight the impact of mTOR feedback and crosstalk regulations on drug-based cancer therapy. This map is available on the Payao platform, a Web 2.0 based community-wide interactive process for creating more accurate and information-rich databases. Thus, this comprehensive map of the mTOR network will serve as a tool to facilitate systems-level study of up-to-date mTOR network components and signaling events toward the discovery of novel regulatory processes and therapeutic strategies for cancer.. null, 6. Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Canada.viji@ebi.ac.ukEMBL-EBIThe mammalian target of rapamycin (mTOR) is a central regulator of cell growth and proliferation. mTOR signaling is frequently dysregulated in oncogenic cells, and thus an attractive target for anticancer therapy. Using CellDesigner, a modeling support software for graphical notation, we present herein a comprehensive map of the mTOR signaling network, which includes 964 species connected by 777 reactions. The map complies with both the systems biology markup language (SBML) and graphical notation (SBGN) for computational analysis and graphical representation, respectively. As captured in the mTOR map, we review and discuss our current understanding of the mTOR signaling network and highlight the impact of mTOR feedback and crosstalk regulations on drug-based cancer therapy. This map is available on the Payao platform, a Web 2.0 based community-wide interactive process for creating more accurate and information-rich databases. Thus, this comprehensive map of the mTOR network will serve as a tool to facilitate systems-level study of up-to-date mTOR network components and signaling events toward the discovery of novel regulatory processes and therapeutic strategies for cancer.A comprehensive map of the mTOR signaling network.Caron Etienne E, Ghosh Samik S, Matsuoka Yukiko Y, Ashton-Beaucage Dariel D, Therrien Marc M, Lemieux Sébastien S, Perreault Claude C, Roux Philippe P PP, Kitano Hiroaki HMechanistic target of rapamycin, 2610315D21Rik, Bx34, FKBP12-rapamycin complex-associated protein, CG5092, Rapamycin and FKBP12 target 1, CT24745, Rapamycin target protein 1, AI327068, flat, FRAP1, tor, Tpr, TPR, FRAP2, mTOR, l(2)k03905, FRAP/TOR, FRAP, DmelCG8274., DmelCG5092, dtor, l(2)k17004, DmTOR, 2.7.11.1, CT16317, CG8274, 5092, MTOR, RAFT1, TOR, Mammalian target of rapamycin, Frap1, CT24817, RAPT1, dTOR, dTor, FK506-binding protein 12-rapamycin complex-associated protein 1extent, AW488255, Sectors, Public Sectors, Tb11, YB, NetrinA, AUTSX5, number, D430049E23Rik, Copyrights, NOVH, CCN3, QM, FBXW4, netrin, Yb, Hek6, Cek6, Public Enterprise, Enterprises, CG2706, fs(1)M104, ENSMUSG00000074119, ERP, APUDoma, Erp, Elkh, Ebi, EBI, Public Domains, Tyrosine-protein kinase receptor EPH-2, EK6, SAP-2, Sap-2, IGFBP9, Public Enterprises, DmelCG4063, IBP-9, neuroendocrine tumour, Kiaa4053, 2.7.10.1, Solute carrier family 6 member 2, L10, Etrp, CT27014, NET1, SLC6A5, Tbl1, TBL1, NAT1, netA, NOVh, Enterprise, NET, Net, Elk, ELK, C130099E04Rik, completeness, Neuronally-expressed EPH-related tyrosine kinase, DmelCG2706, EPH tyrosine kinase 2, DXS648, SAP2, SMAP55, 9330129L11, neuroendocrine tumor, net, neuroendocrine neoplasm, presence., count in organism, Norepinephrine transporter, IGFBP-9, Public, Public Domain, Domains, EPH-like kinase 6, NOV, PlexA1, Domain, Data Base, Plxn1, CG4063, nov, hEK6, CG18657, E-2f, mKIAA4053, E-2g, fs(1)Y[b], l(2)k16213, DmelCG18657, Sector, EPHT2, C130088N23Rik, EG:95B7.8, 2600013D04Rik, PLXN1, DXS648E, netrin AMechanistic target of rapamycin, 2610315D21Rik, MUTYH-Associated Polyposis, methionine aminopeptidase activity, FKBP12-rapamycin complex-associated protein, CG5092, MYH-associated polyposis, autosomal recessive familial adenomatous polyposis, Maps, FRAP1, FRAP2, mTOR, l(2)k03905, FRAP/TOR, DmelCG5092, l(2)k17004, DmTOR, 2.7.11.1, 2, RAFT1, TOR, Mammalian target of rapamycin, familial adenomatous polyposis, RAPT1, MAP, peptidase M activity, autosomal recessive, DmelCG8274, adenomas, RUTBC3, rabGAPLP, L-methionine aminopeptidase activity, Bx34, familial adenomatous polyposis 2, Rapamycin and FKBP12 target 1, RabGAP-5, CT24745, Rapamycin target protein 1, AI327068, flat, tor, Tpr, TPR, MYH-Associated Polyposis, FRAP, dtor, RABGAP5, autosomal recessive multiple colorectal adenomas, CT16317, signalling process, RUSC3, CG8274, 5092, multiple colorectal, MTOR, MAP syndrome, Frap1, CT24817, FAP2, dTOR, dTor, single organism signaling., FK506-binding protein 12-rapamycin complex-associated protein 1, colorectal adenomatous polyposisRAFT-1, 2610315D21Rik, Product, methionine aminopeptidase activity, Languages, determination, FKBP12-rapamycin complex-associated protein, l(2)k03905, Tumor, DmTOR, Serine-Threonine Kinase, Readability, TOR Serine-Threonine Kinase, Pharmaceutical Product, 2, Kinase, Software Engineering, RAFT1, Mammalian target of rapamycin, FK506 Binding Protein 12-Rapamycin Associated Protein 1, Computer Program, peptidase M activity, adenomas, imprinted and ancient gene protein, treatment, Multicase, FKBP12 Rapamycin Associated Protein, rabGAPLP, L-methionine aminopeptidase activity, Biology, non-developmental growth of a unicellular organism, Open, Computer Programs and Programming, RabGAP-5, metabolic process resulting in cell growth, dtor, medicine, malignant neoplasm, RUSC3, Pharmaceutical, disease management, cellular growth, Therapies, Malignancies, RAFT 1 Protein, dTOR, dTor, FK506-binding protein 12-rapamycin complex-associated protein 1, single organism signaling, Tumors, Therapy, Mechanistic target of rapamycin, anatomical protrusion, wide/broad, metabolism resulting in cell growth, MYH-associated polyposis, autosomal recessive familial adenomatous polyposis, Maps, FK506 Binding Protein 12 Rapamycin Associated Protein 1, Source Softwares, Software Tools, Programs, Program, Computer Applications, Rapamycin Target Protein, mTOR Serine-Threonine Kinase, Benign, non-developmental cell growth, Computer Applications Software, Computer Applications Softwares, Pharmaceutic, Softwares, regulator, mTOR Serine-Threonine, Rapamycin Protein Target, RAPT1, autosomal recessive, RUTBC3, Software Applications, Dialects, Review, Source Software, Rapamycin and FKBP12 target 1, Benign Neoplasms, TOR Kinase, Treatments, RABGAP5, Malignant Neoplasms, Applications, wide, spine, 5092, multiple colorectal, Review of Reported Cases, Feedbacks, E430016J11Rik, Target of Rapamycin Proteins, Computer Software Applications, Malignant Neoplasms., RAFT-1 Protein, CG5092, Neoplasms, Benign Neoplasm, Computer, broad, Ximpact, Malignant, l(2)k17004, TOR Serine Threonine Kinases, protrusion, FKBP12 Rapamycin Complex Associated Protein, mTOR Serine-Threonine Kinases, TOR, mTOR Serine Threonine Kinases, familial adenomatous polyposis, Application, MAP, DmelCG8274, Drugs, Open Source Softwares, study, Serine-Threonine Kinases, Bx34, growth of cell, Malignancy, Academic, Software Application, familial adenomatous polyposis 2, Open Source Software, flat, tor, Tpr, TPR, Mechanistic Target of Rapamycin Protein, Computer Software Application, autosomal recessive multiple colorectal adenomas, Neoplasias, drugs, Tools, Target of Rapamycin Protein, species, Preparation, Frap1, CT24817, Pharmaceuticals, Cancer, Applications Software, Products, Open Source, TOR Serine Threonine Kinase, TOR Kinases, Computer Software, MUTYH-Associated Polyposis, Malignant Neoplasm, TOR Serine-Threonine, drug, FRAP1, FRAP2, mTOR, FRAP/TOR, DmelCG5092, Cell, impact-a, Tool, cell expansion, 2.7.11.1, Software Tool, Review Literature, MT, Rapamycin, Protein, Systems, chemical analysis, Neoplasm, IMPACT, imprinted and ancient gene protein homolog, Software, FKBP12-Rapamycin Complex-Associated Protein, primary cancer, Protein Target, Pharmaceutic Preparations, Kinases, Mammalian Target of Rapamycin, FKBP12-Rapamycin Associated Protein, Engineering, CT24745, Rapamycin target protein 1, AI327068, Cancers, Dialect, Understanding, MYH-Associated Polyposis, FRAP, mTOR Protein, malignant tumor, Drug, Computer Programs, Preparations, CT16317, Applications Softwares, signalling process, Therapeutic, CG8274, MTOR, Treatment, MAP syndrome, mTOR Serine Threonine Kinase, assay, Pharmaceutical Products, RWDD5, Neoplasia, FAP2, Pharmaceutical Preparation, colorectal adenomatous polyposisfalseCaron2010_mTOR_SignalingNetwork This model originates from BioModels Database: A Database of Annotated Published Models (http://www.ebi.ac.uk/biomodels/). It is copyright (c) 2005-2011 The BioModels.net Team. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information. In summary, you are entitled to use this encoded model in absolutely any manner you deem suitable, verbatim, or with modification, alone or embedded it in a larger context, redistribute it, commercially or not, in a restricted way or not.. To cite BioModels Database, please use: Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novère N, Laibe C (2010) BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol., 4:92. 2011-06-232005-01-012010-12-22MODEL101222000221179025MODEL1012220002GO:00319299606